<?xml version='1.0' encoding='utf-8'?>
<document id="27128836"><sentence text="Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor." /><sentence text="Dutogliptin is a selective dipeptidyl peptidase-4 inhibitor shown to be efficacious and safe in patients with type 2 diabetes mellitus (T2DM)"><entity charOffset="0-11" id="DDI-PubMed.27128836.s2.e0" text="Dutogliptin" /></sentence><sentence text=" Population pharmacokinetic (PK) analysis of dutogliptin was performed based on data collected in 561 healthy subjects and patients with T2DM enrolled in Phase I and II studies to assess sources of variability and support dosing rationale" /><sentence text=" The effect of extrinsic (formulations, fed/fasting conditions, potential drug-drug interaction with metformin) and intrinsic (baseline characteristics, markers of renal function, renal impairment category, and disease status) covariates was evaluated using non-linear mixed effect modeling"><entity charOffset="101-110" id="DDI-PubMed.27128836.s4.e0" text="metformin" /></sentence><sentence text=" Plasma concentrations of dutogliptin were best fitted with a two-compartment model with a first-order rate constant of absorption (Ka) and a lag time" /><sentence text=" No differences were observed between healthy subjects and patients with T2DM" /><sentence text=" Apparent clearance (CL/F) and terminal elimination half-life of dutogliptin were 176 L/h and 12" /><sentence text="2 hours, respectively" /><sentence text=" Typical CL/F values in patients with mild and moderate renal impairment were 121 and 79 L/h, respectively" /><sentence text=" No drug-drug interaction was observed with metformin"><entity charOffset="44-53" id="DDI-PubMed.27128836.s10.e0" text="metformin" /></sentence><sentence text=" These results suggest that a reduction in dosing from 400 to 200 mg daily is warranted in T2DM patients with moderate renal impairment" /><sentence text=" No dose adjustments were deemed necessary for other evaluated patient characteristics and coadministration with metformin"><entity charOffset="113-122" id="DDI-PubMed.27128836.s12.e0" text="metformin" /></sentence><sentence text="" /></document>